| Lembo, Anthony |
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis |
|
|
| Recruiting | 2 | 288 | US | CIN-102 Dose 15mg or 10mg, Placebo | CinDome Pharma, Inc. | Diabetic Gastroparesis | 09/25 | 09/25 | | |
| Active, not recruiting | N/A | 40 | US | FODMAP diet | Beth Israel Deaconess Medical Center, University of Michigan | Irritable Bowel Syndrome | 06/21 | 06/25 | | |
NCT06257472: Efficacy of Virtual Reality (VR) for Irritable Bowel Syndrome |
|
|
| Recruiting | N/A | 75 | US | Virtual Reality Headset | Anthony Lembo, Cedars-Sinai Medical Center | IBS - Irritable Bowel Syndrome | 08/25 | 08/25 | | |
| Not yet recruiting | N/A | 72 | US | SynerGI, Sham VR | Christopher Almario, The Cleveland Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | IBS - Irritable Bowel Syndrome | 03/26 | 06/26 | | |
| Leathers, Vickie |
NCT05207865: Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention |
|
|
| Completed | 4 | 255 | US | Rimegepant, BHV-3000 | Pfizer | Migraine, Episodic Migraine, Phonophobia, Photophobia | 07/24 | 07/24 | | |
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis |
|
|
| Recruiting | 2 | 288 | US | CIN-102 Dose 15mg or 10mg, Placebo | CinDome Pharma, Inc. | Diabetic Gastroparesis | 09/25 | 09/25 | | |
| Peery, Marsha |
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis |
|
|
| Recruiting | 2 | 288 | US | CIN-102 Dose 15mg or 10mg, Placebo | CinDome Pharma, Inc. | Diabetic Gastroparesis | 09/25 | 09/25 | | |
| Balay, Jessica |
| Completed | 3 | 200 | US | Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator, Twice Daily - Active, Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator, Once Daily - Active, Twice daily placebo suppository administered with Sephure applicator, Twice Daily - Placebo | Cristcot LLC, Cristcot HCA LLC | Ulcerative Proctitis | 07/24 | 09/24 | | |
| Recruiting | 3 | 852 | Europe, Canada, US, RoW | VE303, Placebo | Vedanta Biosciences, Inc. | Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious | 06/27 | 10/27 | | |
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis |
|
|
| Recruiting | 2 | 288 | US | CIN-102 Dose 15mg or 10mg, Placebo | CinDome Pharma, Inc. | Diabetic Gastroparesis | 09/25 | 09/25 | | |
NCT06587828: A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients with Autoimmune Disease |
|
|
| Recruiting | N/A | 300 | US | Companion blood samples with procedure | TScan Therapeutics, Inc. | Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma, Ankylosing Spondylitis, Celiac Disease, Non-radiographic Axial Spondyloarthritis (nr-axSpA), Crohn's Disease, Birdshot Chorioretinitis | 01/25 | 06/25 | | |
| Active, not recruiting | N/A | 44467 | US | | Guardant Health, Inc., Premier Research Group plc | Colorectal Cancer | 03/24 | 12/25 | | |
NCT03789162: Blood and Stool Sample Collection in Subjects with a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast |
|
|
| Active, not recruiting | N/A | 1500 | Canada, US | | Exact Sciences Corporation | Colorectal Cancer | 04/25 | 04/25 | | |
ALTUS, NCT05064553: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk |
|
|
| Recruiting | N/A | 2500 | US | Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test | Exact Sciences Corporation | Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer | 01/25 | 04/26 | | |
| Botte, Jennifer |
PREVAIL, NCT05472090: A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection |
|
|
| Completed | 2 | 63 | US | TNX-102 SL, Placebo SL Tablet | Tonix Pharmaceuticals, Inc. | Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID | 07/23 | 07/23 | | |
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis |
|
|
| Recruiting | 2 | 288 | US | CIN-102 Dose 15mg or 10mg, Placebo | CinDome Pharma, Inc. | Diabetic Gastroparesis | 09/25 | 09/25 | | |
| Herman, Tracey |
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis |
|
|
| Recruiting | 2 | 288 | US | CIN-102 Dose 15mg or 10mg, Placebo | CinDome Pharma, Inc. | Diabetic Gastroparesis | 09/25 | 09/25 | | |
| Fernandez, Deysi |
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis |
|
|
| Recruiting | 2 | 288 | US | CIN-102 Dose 15mg or 10mg, Placebo | CinDome Pharma, Inc. | Diabetic Gastroparesis | 09/25 | 09/25 | | |
